Related Experiment Videos
Successful surfactant replacement therapy in two infants with ARDS due to chlamydial pneumonia
Insights
Repeated doses of bovine natural surfactant (Survanta) successfully treated severe respiratory failure in two infants with chlamydial pneumonia and adult respiratory distress syndrome (ARDS). This rescue therapy improved oxygenation and reduced ventilator support, preventing chronic lung disease.
Area of Science:
- Neonatology
- Pulmonology
- Pediatric Critical Care
Background:
- Chlamydial pneumonia can lead to severe respiratory failure and adult respiratory distress syndrome (ARDS) in infants.
- Mechanical ventilation with high oxygen concentrations may be insufficient in severe cases.
Observation:
- Two former premature infants developed ARDS following chlamydial pneumonia.
- Despite maximal mechanical ventilation and 100% oxygen, both infants experienced severe hypoxia.
Findings:
- Rescue surfactant treatment with bovine natural surfactant (Survanta) led to rapid improvement in oxygenation (PaO2/FiO2 ratio increase) and reduced ventilatory pressure requirements.
- Both infants received repeated surfactant doses and survived without developing chronic lung disease.
Implications:
- Surfactant replacement therapy is a viable rescue option for infant ARDS secondary to pneumonia.
- Early and repeated surfactant administration may prevent long-term respiratory complications in critically ill infants.
Abstract:
We report two cases of adult respiratory distress syndrome (ARDS) treated successfully with repeated doses of a bovine natural surfactant (Survanta). Two former premature infants developed severe respiratory failure as a consequence of a chlamydial pneumonia at the age of 3 or 12 weeks, respectively. As both patients were threatened by hypoxia in spite of mechanical ventilation with maximal pressures using 100% O2 and as the X-rays were compatible with the diagnosis of ARDS, we decided to perform rescue surfactant treatment. Following surfactant instillation, marked improvement in oxygenation and ventilatory requirements was observed. Within 2 h after surfactant replacement, the PaO2/FiO2 ratio increased from 52 to 84 (case 1) and from 35 to 94 (case 2), and the peak inspiratory pressure could be reduced from 47 to 40 cm H2O and from 35 to 28 cm H2O, respectively. Both infants received a second surfactant dose about 10 h after the initial treatment and survived without developing chronic lung disease.